Rubosixtaurin and other PKC inhibitors in diabetic retinopathy and macular edema. Review.
Diabetic retinopathy (DR) and diabetic macular edema (DME) are frequent long term ocular complications in diabetic patients and may produce serious effects on visual acuity (VA), sometimes leading to blindness. The high and increasing prevalence of diabetes worldwide suggests that both complications will continue to be the main cause of vision loss and associated impairment for a long time [1]. The development and progression of DR is related to blood glucose concentration and is slowed by intensive glycemic control [2].
Gálvez
M Isabel López
MI
IOBA, Campus Miguel Delibes, Universidad de Valladolid, Valladolid, Spain. maribel@ioba.med.uva.es
D003930:Diabetic Retinopathy / Q000188:drug therapy*; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans; D006943:Hyperglycemia / Q000150:complications; D007211:Indoles / Q000627:therapeutic use*; D008269:Macular Edema / Q000188:drug therapy*; D008301:Maleimides / Q000627:therapeutic use*; D009389:Neovascularization, Pathologic / Q000209:etiology; D011493:Protein Kinase C / Q000037:antagonists & inhibitors*
D004791:Enzyme Inhibitors; D007211:Indoles; D008301:Maleimides; C099154:ruboxistaurin; D011493:Protein Kinase C